Skip to navigation Skip to content

News

Share

FDA issues warning about medications containing oxybutynin

July 15, 2011

Some of medications (Ditropan®, Ditropan XL®, Gelnique® gel, Oxytrol® transdermal patch) used to treat urinary problems in people with MS contain oxybutynin. The FDA has added a warning to the labeling of these medications stating that angioedema (a swelling similar to hives that occurs under the skin) of the face, lips, tongue and/or larynx has been reported with oxybutynin taken orally.  In some cases, angioedema occurred after the first dose; in other cases it occurred with later doses. The swelling was severe enough in some individuals to interfere with breathing and required hospitalization and emergency treatment. Although this reaction appears to be relatively rare, given the many years that oxybutynin has been used safely and successfully by people with MS and others, any person taking a medication containing oxybutynin who experiences swelling of the tongue or throat or difficulty breathing should stop the medication and seek immediate medical attention. Individuals who have questions or concerns about this medication should discuss them with their physician.

Read more about bladder dysfunction in MS.

About Multiple Sclerosis

Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.